{"entity": "researcher", "timestamp": "2026-09-24T05:54:22.116Z", "family": "Grande", "given": "Giulia", "initials": "G", "orcid": "0000-0001-6312-3815", "affiliations": ["Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden. giulia.grande@ki.se.", "Stockholm Gerontology Research Center, Stockholm, Sweden. giulia.grande@ki.se."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/560ca11ae102481a8e29703d6c395553.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/560ca11ae102481a8e29703d6c395553"}}, "publications": [{"entity": "publication", "iuid": "c35597fd7be64f3ba4de9f422502dfde", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/c35597fd7be64f3ba4de9f422502dfde.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/c35597fd7be64f3ba4de9f422502dfde"}}, "title": "Blood biomarkers of Alzheimer's disease and progression across different stages of cognitive decline in the community.", "authors": [{"family": "Valletta", "given": "Martina", "initials": "M", "orcid": "0000-0003-0139-8287", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/40c63a55168d4a35bdd9d91428e39448.json"}}, {"family": "Vetrano", "given": "Davide Liborio", "initials": "DL", "orcid": "0000-0002-3099-4830", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/3473c98810f247f7805ea747af1fdbbe.json"}}, {"family": "Gregorio", "given": "Caterina", "initials": "C", "orcid": "0000-0002-8163-1634", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/a81270d6a50243c0a64044b16384c010.json"}}, {"family": "Rizzuto", "given": "Debora", "initials": "D"}, {"family": "Winblad", "given": "Bengt", "initials": "B", "orcid": "0000-0002-0011-1179", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/fa53d96890814cab88c6adaf1aaf4b8d.json"}}, {"family": "Canevelli", "given": "Marco", "initials": "M"}, {"family": "Andersson", "given": "Sarah", "initials": "S"}, {"family": "Dale", "given": "Matilda", "initials": "M", "orcid": "0000-0002-5788-7744", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/ceec63ec0dea45eaa5ad3c4d34b10959.json"}}, {"family": "Fredolini", "given": "Claudia", "initials": "C", "orcid": "0000-0002-7674-2014", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/cda0965cae2344aa9aaf9b1c5605b378.json"}}, {"family": "Laukka", "given": "Erika J", "initials": "EJ"}, {"family": "Fratiglioni", "given": "Laura", "initials": "L"}, {"family": "Grande", "given": "Giulia", "initials": "G", "orcid": "0000-0001-6312-3815", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/560ca11ae102481a8e29703d6c395553.json"}}], "type": "journal article", "published": "2025-11-23", "journal": {"title": "Nat Commun", "issn": "2041-1723", "volume": "16", "issue": "1", "pages": "10412", "issn-l": "2041-1723"}, "abstract": "Blood biomarkers of Alzheimer's disease (AD) are promising for dementia prediction, but their association with progression across intermediate stages of cognitive decline in the general population remains unclear. We followed 2148 dementia-free individuals from a Swedish population-based cohort for up to 16 years. Associations between baseline AD blood biomarkers and transitions between normal cognition, mild cognitive impairment (MCI), and dementia were examined. Lower amyloid-\u03b242/40 ratio and higher phosphorylated-tau181 (p-tau181), p-tau217, total-tau, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were associated with faster progression from MCI to all-cause and AD dementia, with the strongest associations for NfL and p-tau217. Elevated NfL and GFAP were linked to reduced MCI reversion to normal cognition, whereas no biomarker was associated with MCI development from normal cognition. These findings show robust group-level associations and indicate that AD blood biomarkers may help stratify dementia risk at the MCI stage in the community.", "doi": "10.1038/s41467-025-66728-2", "pmid": "41276530", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC12644782"}, {"db": "pii", "key": "10.1038/s41467-025-66728-2"}], "notes": [], "created": "2026-09-23T09:08:28.915Z", "modified": "2026-09-23T09:08:29.063Z"}, {"entity": "publication", "iuid": "edf36a43bbf54946b3637973de3b5c3f", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/edf36a43bbf54946b3637973de3b5c3f.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/edf36a43bbf54946b3637973de3b5c3f"}}, "title": "Blood-based biomarkers of Alzheimer's disease and incident dementia in the community.", "authors": [{"family": "Grande", "given": "Giulia", "initials": "G", "orcid": "0000-0001-6312-3815", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/560ca11ae102481a8e29703d6c395553.json"}}, {"family": "Valletta", "given": "Martina", "initials": "M", "orcid": "0000-0003-0139-8287", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/40c63a55168d4a35bdd9d91428e39448.json"}}, {"family": "Rizzuto", "given": "Debora", "initials": "D"}, {"family": "Xia", "given": "Xin", "initials": "X"}, {"family": "Qiu", "given": "Chengxuan", "initials": "C", "orcid": "0000-0003-1922-4912", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/a4a3f19bc7e049b09dd1d1c8a5b2f621.json"}}, {"family": "Orsini", "given": "Nicola", "initials": "N"}, {"family": "Dale", "given": "Matilda", "initials": "M", "orcid": "0000-0002-5788-7744", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/ceec63ec0dea45eaa5ad3c4d34b10959.json"}}, {"family": "Andersson", "given": "Sarah", "initials": "S"}, {"family": "Fredolini", "given": "Claudia", "initials": "C", "orcid": "0000-0002-7674-2014", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/cda0965cae2344aa9aaf9b1c5605b378.json"}}, {"family": "Winblad", "given": "Bengt", "initials": "B", "orcid": "0000-0002-0011-1179", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/fa53d96890814cab88c6adaf1aaf4b8d.json"}}, {"family": "Laukka", "given": "Erika J", "initials": "EJ"}, {"family": "Fratiglioni", "given": "Laura", "initials": "L"}, {"family": "Vetrano", "given": "Davide L", "initials": "DL", "orcid": "0000-0002-3099-4830", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/3473c98810f247f7805ea747af1fdbbe.json"}}], "type": "journal article", "published": "2025-06-00", "journal": {"title": "Nat. Med.", "issn": "1546-170X", "volume": "31", "issue": "6", "pages": "2027-2035", "issn-l": "1078-8956"}, "abstract": "Evidence regarding the clinical validity of blood biomarkers of Alzheimer's disease (AD) in the general population is limited. We estimated the hazard and predictive performance of six AD blood biomarkers for incident all-cause and AD dementia-the ratio of amyloid-\u03b2 42 to amyloid-\u03b2 40 and levels of tau phosphorylated at T217 (p-tau217), tau phosphorylated at T181 (p-tau181), total tau, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP)-in a cohort of 2,148 dementia-free older adults from Sweden, who were followed for up to 16 years. In multi-adjusted Cox regression models, elevated baseline levels of p-tau181, p-tau217, NfL, and GFAP were associated with a significantly increased hazard for all-cause and AD dementia, displaying a non-linear dose-response relationship. Elevated concentrations of p-tau181, p-tau217, NfL, and GFAP demonstrated strong predictive performance (area under the curve ranging from 70.9% to 82.6%) for 10-year all-cause and AD dementia, with negative predictive values exceeding 90% but low positive predictive values (PPVs). Combining p-tau217 with NfL or GFAP further improved prediction, with PPVs reaching 43%. Our findings suggest that these biomarkers have the potential to rule out impending dementia in community settings, but they might need to be combined with other biological or clinical markers to be used as screening tools.", "doi": "10.1038/s41591-025-03605-x", "pmid": "40140622", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC12176656"}, {"db": "pii", "key": "10.1038/s41591-025-03605-x"}], "notes": [], "created": "2026-09-23T06:49:46.343Z", "modified": "2026-09-23T07:25:41.142Z"}]}